MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

ASCO 2024

Annual Meeting American Society of Clinical Oncology (ASCO) – May 31-June 4, 2024 / Chicago, IL

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

First-in-Human Trial of M9140, an Anti-CEACAM5 Antibody–Drug Conjugate (ADC) with Exatecan Payload, in Patients (pts) with Metastatic Colorectal Cancer (mCRC)

Kopetz | Oral #3000

Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial

Motzer | Oral #4508

A Phase I Study of Highly Potent Oral ATR Inhibitor (ATRi) Tuvusertib plus Oral PARP Inhibitor (PARPi) Niraparib in Patients with Solid Tumors

Yap | Oral #3018

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden

Bellmunt | Poster #4566

Pharmacodynamic (PD) and Immunophenotyping Analyses of ATR Inhibitor (ATRi) Tuvusertib + ATM Inhibitor (ATMi) Lartesertib in a Phase 1b Study of Patients with Advanced Unresectable Solid Tumours

Boni | Poster #2612

Phase 2 Study of Xevinapant + Chemoradiotherapy (CRT) vs Placebo + CRT in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN): A Post Hoc Activity Analysis by Blinded Independent Review Committee Evaluation

Bourhis | e-abstract #e18039

Real-World (rw) Treatment (tx) Patterns and Clinical Outcomes in Patients (pts) with Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC): Insights from the US Oncology Network Electronic Health Record (EHR)

Bupathi | e-abstract #e16551

Real-World (rw) Treatment (tx) Patterns, Sequencing, and Outcomes in US Patients (pts) with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Treated with Avelumab First-Line Maintenance (1LM)

Carson | e-abstract #e16621

Age and other Criteria Influencing Nontreatment of Patients with Locally Adanced or Metastatic Urothelial Carncinoma: Results of a Physician Survey in 5 European Countries

Gupta | Poster #4570

Costs Associated with Novel First-Line (1L) Treatments in Patients (pts) with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) from a United States (US) Medicare and Commercial Payer Perspective

Ike | e-abstract #e16552

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 Trial Patients with Histological Subtypes

Loriot | Poster #4567

Health-Related Quality of Life (HRQoL) with Tepotinib in Patients with MET Exon 14 (MET ex14) Skipping Non-Small Cell Lung Cancer (NSCLC) with Brain, Liver, Adrenal or Bone Metastases in the Phase II VISION Trial

Reinmuth | Poster #8575

Informing Optimal Treatment (tx) Sequences for Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) in the United States: Results of a Clinical Simulation Modeling Exercise

Sanchez Alvarez | e-abstract #e13514

Pharmacokinetic (PK) and Pharmacodynamic (PD) Findings from a Phase 1b Study of ATR Inhibitor Tuvusertib + Anti-PD-L1 Avelumab in Patients with Advanced Unresectable Solid Tumors

Tolcher | Poster #2614

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options:

ASCO 2024

Cookie Disclaimer

Welcome to EMD Serono Medical Information!